4 published verifications about CYP2C19 CYP2C19 ×
“The CYP2C19 gene has high genetic variability with 39 possible alleles that influence the rate of medication metabolism.”
The claim is broadly accurate: CYP2C19 is highly variable genetically, and that variation can change how quickly certain medicines are metabolized. The main caveat is that “39 alleles” is not a settled, timeless number; authoritative sources report slightly different counts depending on date and counting method. The practical point about variability affecting drug response is well supported.
“The human enzyme CYP2C19 metabolizes about 10% of commonly prescribed medications, including some antidepressants, proton pump inhibitors, clopidogrel, and voriconazole.”
Reliable medical references support the statement that CYP2C19 is involved in metabolizing about 10% of commonly prescribed drugs. The cited examples—some antidepressants, proton pump inhibitors, clopidogrel, and voriconazole—are all well-established CYP2C19-related medications. The exact percentage can vary by source and definition, but that caveat does not change the main takeaway.
“Scientific studies report an association between CYP2C19 genetic variants and major depressive disorder, longer depressive episodes, and greater depressive symptom severity.”
Published studies do report these associations. Systematic reviews and several primary studies describe links between CYP2C19 variants and depression risk, longer episodes, or greater symptom severity, even though results are mixed overall. The claim stays within what the evidence supports because it says studies report an association, not that the association is proven or universal.
“Genetic variants in the CYP2C19 gene that reduce CYP2C19 enzyme activity can contribute to relatively treatment-resistant depression by reducing the metabolism of some antidepressant medications.”
Reduced-function CYP2C19 variants do slow the metabolism of some antidepressants, but the best evidence does not show that this usually causes antidepressants to be less effective. These variants are more consistently associated with higher drug levels and more side effects, sometimes alongside equal or better remission. They can contribute indirectly to harder-to-treat depression through intolerance or discontinuation, but that is not the main or best-supported pattern.